Roivant Sciences Financial Statements
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Roivant Sciences revenue and earnings
In fiscal 2025, Roivant Sciences generated $8.3 million in revenue, down 71.6% from fiscal 2024, its first annual decline since 2024. Roivant Sciences reported a net loss of $299.8 million, compared with a loss of $172.0 million a year earlier. Operating margin was -6235.7%.
Diluted earnings per share came in at -$0.54. Over the last 5 fiscal years, ROIV's revenue has grown at a -19.1% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Roivant Sciences income statement (annual)
| Fiscal year (USD) | FY 20252026-03-31 | FY 20242025-03-31 | FY 20232024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20202021-03-31 |
|---|---|---|---|---|---|---|
| Revenue | 8.26M | 29.05M | 32.71M | 31.53M | 55.29M | 23.80M |
| Revenue growth (YoY) | -71.57% | -11.19% | +3.75% | -42.97% | +132.34% | — |
| Operating Expenses | 1.29B | 1.14B | 884.09M | 938.29M | 1.41B | 1.09B |
| Research & Development | 681.81M | 550.41M | 439.91M | 454.06M | 483.04M | 236.63M |
| Selling, General & Admin | — | — | 687.44M | 600.51M | 775.03M | — |
| Operating Income | -515.07M | -1.00B | 4.50B | -906.76M | -1.35B | -1.07B |
| Interest Expense | — | — | 34.78M | 27.97M | 7.04M | 2.81M |
| Other Income (Expense) | 4.01M | -10.72M | -13.56M | -486.00K | 3.24M | -8.70M |
| Pretax Income | -264.58M | -681.59M | 4.57B | -884.99M | -923.75M | -898.55M |
| Income Tax | 133.33M | 48.17M | 21.50M | 4.08M | 369.00K | 1.69M |
| Net Income | -299.77M | -171.98M | 4.35B | -1.01B | -845.26M | -809.23M |
| Net Income growth (YoY) | — | -103.95% | — | — | — | — |
| EPS (Basic) | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.28 |
| EPS (Diluted) | -0.54 | -0.24 | 5.23 | -1.42 | -1.26 | -1.28 |
| Shares Outstanding (Basic) | 693.86M | 725.40M | 783.25M | 712.79M | 669.75M | 630.05M |
| Shares Outstanding (Diluted) | 693.86M | 725.40M | 831.05M | 712.79M | 669.75M | 630.05M |
| EBITDA | -511.72M | -989.22M | 4.52B | -887.91M | -1.35B | — |
| Operating Margin | -6235.69% | -3453.32% | 13746.93% | -2875.87% | -2444.82% | -4500.52% |
| Net Margin | -3629.19% | -591.96% | 13294.18% | -3200.22% | -1528.89% | -3400.86% |
This table shows 6 annual periods of Roivant Sciences's income statement, from FY 2025 back to FY 2020, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ROIV's reporting calendar. What is a income statement?